E-viri
Recenzirano
-
Hussain, Khawar; Kanji, Alpa; Zaheri, Shirin; Malek, Dalila; Terlizzo, Monica; Weir, Justin; Turajlic, Samra; Fearfield, Louise
Clinical and experimental dermatology, 03/2023, Letnik: 48, Številka: 3Journal Article
Checkpoint inhibitor therapy (CPI) has significantly improved overall survival in several cancers, including metastatic melanoma and in the adjuvant setting. Cutaneous immune-related adverse events secondary to CPI are commonly observed; however, the development of psoriasis or exacerbation of existing psoriasis has not been widely reported and management can be challenging.
